Target intelligence / Profile preview

Kynurenine monooxygenase (KMO)

Target: KMO
Molecular classification: Enzyme, Flavin-dependent monooxygenase

Overview

Kynurenine monooxygenase (KMO) is a flavin-dependent monooxygenase enzyme that catalyzes the hydroxylation of L-kynurenine to 3-hydroxy-L-kynurenine in the kynurenine pathway, a primary route for tryptophan catabolism. It plays a critical role in determining the balance between neurotoxic and neuroprotective metabolites. KMO is considered an attractive drug target for various diseases including neurodegenerative diseases and cancer-related inflammation.

Mechanism of action

Inhibition of KMO activity

Biological functions

Tryptophan catabolismNAD+ biosynthesisRegulation of neurotoxic/neuroprotective tryptophan metabolites

Disease associations

Neurodegenerative diseases (Alzheimer's disease, Huntington's disease, Parkinson's disease)Cancer-related inflammation

Beyond the preview

Go deeper on Kynurenine monooxygenase (KMO).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kynurenine monooxygenase (KMO).

Explore the full profile